POSSIBLE EFFECT OF OAS1 AND TMPRSS6 BUT NOT DPP4 AND ZNF335 POLYMORPHISMS ON COVID-19 SEVERITY IN THE CZECH POPULATION
Authors | |
---|---|
Year of publication | 2023 |
Type | Article in Periodical |
Magazine / Source | Central European journal of public health |
MU Faculty or unit | |
Citation | |
web | https://cejph.szu.cz/artkey/cjp-202304-0002_possible-effect-of-oas1-and-tmprss6-but-not-dpp4-and-znf335-polymorphisms-on-covid-19-severity-in-the-czech-pop.php |
Doi | http://dx.doi.org/10.21101/cejph.a7906 |
Keywords | COVID-19; DPP4; OAS1; polymorphism; SARS-CoV-2; severity; TMPRSS6; ZNF335 |
Description | Objectives: The acute respiratory syndrome, known as COVID-19, is characterised by high morbidity and increased mortality. Genetic factors may partially explain the differences in susceptibility to and severity of COVID-19. Methods: We have analysed common functional polymorphisms within the OAS1 (rs4767027), TMPRSS6 (rs855791), DPP4 (rs3788979), and ZNF335 (rs3848719) genes in SARS-CoV-2 positive subjects (n = 521, different disease severity) and in population controls (n = 2,559 subjects, COVID-19 status unknown). Results: Neither DPP4 nor ZNF335 were associated with disease susceptibility or severity in the Czech population in any of the models used for calculation. T allele carriers of the OAS1 polymorphism seem to be protective against symptomatic COVID-19 (p = 0.002 calculated for trend; asymptomatic, symptomatic, hospitalised). Similarly, within the TMPRSS6, minor TT homozygotes associated with lower plasma Fe concentrations were underrepresented in the overall patient group (p = 0.044; OR = 0.77, 95% CI: 0.59-0.99), and the difference was mainly driven by the severe COVID-19 subjects. In general, risky homozygotes of these two polymorphisms were less frequent than expected in the group of hospitalised COVID-19 survivors. Conclusions: Common variants within OAS1 (rs4767027) and TMPRSS6 (rs855791) play some role in COVID-19 pathology in the Czech Caucasian population. Whether the depletion of minor allele carriers of these two variants is associated with increased COVID-19 mortality, needs to be analysed in an external confirmatory study. |